Atorvastatin treatment prevents alterations in coronary smooth muscle nuclear Ca2+ signaling in diabetic dyslipidemia

B. R. Wamhoff, J. L. Dixon, Michael Sturek

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Atorvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, alters bulk myoplasmic Ca2+regulation and inhibits phenotypic modulation and proliferation of vascular smooth muscle in culture. Nuclear Ca2+ (Can) signaling is tightly coupled to transcriptional events and cell growth. Therefore, we hypothesized that in vivo treatment with atorvastatin would attenuate alterations in mitogen-induced Can signaling associated with coronary atherosclerosis. Three groups of male Yucatan pigs were treated for 20 weeks: controls, alloxan-induced diabetics fed an atherogenic diet and diabetics fed an atherogenic diet plus atorvastatin (80 mg/day). Right coronary artery single-cell cytosolic Ca2+ (Cac) and Can responses to the mitogen endothelin-1 (5 × 10-8M) were measured by laser confocal microscopy using the calcium indicator Fluo-4. We observed a 39% increase in Cac and a 52% increase in Can responses to endothelin-1 in cells from diabetic dyslipidemic arteries compared to control. These alterations were prevented in animals treated with atorvastatin. We show that during proliferation, the nucleus of a smooth muscle cell becomes rounded and loses the characteristic multilobular shape, clefts and invaginations. Consistent with this, a redistribution of Ca2+ stores from a transnuclear morphology in controls to a more perinuclear morphology occurred in cells from diabetic dyslipidemic arteries and was prevented by atorvastatin. In addition, the peak Can responses to endothelin-1 were inversely correlated (r = 0.712) with the extent of the transnuclear distribution of Ca2+ stores and directly correlated (r = 0.874) with the extent of atherosclerosis, as assessed in vivo by intravascular ultrasound. These findings indicate that chronic treatment with atorvastatin directly decreases mitogen-induced Can mobilization, which we suggest is related to the spatial localization of Can stores.

Original languageEnglish (US)
Pages (from-to)208-220
Number of pages13
JournalJournal of Vascular Research
Volume39
Issue number3
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Dyslipidemias
Smooth Muscle
Endothelin-1
Mitogens
Atherogenic Diet
Confocal Microscopy
Arteries
Alloxan
Vascular Smooth Muscle
Smooth Muscle Myocytes
Atorvastatin Calcium
Coronary Artery Disease
Atherosclerosis
Coronary Vessels
Oxidoreductases
Swine
Calcium
Growth

Keywords

  • Cholesterol
  • Confocal microscopy
  • Electron microscopy
  • Endothelin
  • Intravascular ultrasound
  • Porcine
  • Triglyceride

ASJC Scopus subject areas

  • Physiology

Cite this

Atorvastatin treatment prevents alterations in coronary smooth muscle nuclear Ca2+ signaling in diabetic dyslipidemia. / Wamhoff, B. R.; Dixon, J. L.; Sturek, Michael.

In: Journal of Vascular Research, Vol. 39, No. 3, 2002, p. 208-220.

Research output: Contribution to journalArticle

@article{d8220cd4a1c5490e95d95ace2c6b4d40,
title = "Atorvastatin treatment prevents alterations in coronary smooth muscle nuclear Ca2+ signaling in diabetic dyslipidemia",
abstract = "Atorvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, alters bulk myoplasmic Ca2+regulation and inhibits phenotypic modulation and proliferation of vascular smooth muscle in culture. Nuclear Ca2+ (Can) signaling is tightly coupled to transcriptional events and cell growth. Therefore, we hypothesized that in vivo treatment with atorvastatin would attenuate alterations in mitogen-induced Can signaling associated with coronary atherosclerosis. Three groups of male Yucatan pigs were treated for 20 weeks: controls, alloxan-induced diabetics fed an atherogenic diet and diabetics fed an atherogenic diet plus atorvastatin (80 mg/day). Right coronary artery single-cell cytosolic Ca2+ (Cac) and Can responses to the mitogen endothelin-1 (5 × 10-8M) were measured by laser confocal microscopy using the calcium indicator Fluo-4. We observed a 39{\%} increase in Cac and a 52{\%} increase in Can responses to endothelin-1 in cells from diabetic dyslipidemic arteries compared to control. These alterations were prevented in animals treated with atorvastatin. We show that during proliferation, the nucleus of a smooth muscle cell becomes rounded and loses the characteristic multilobular shape, clefts and invaginations. Consistent with this, a redistribution of Ca2+ stores from a transnuclear morphology in controls to a more perinuclear morphology occurred in cells from diabetic dyslipidemic arteries and was prevented by atorvastatin. In addition, the peak Can responses to endothelin-1 were inversely correlated (r = 0.712) with the extent of the transnuclear distribution of Ca2+ stores and directly correlated (r = 0.874) with the extent of atherosclerosis, as assessed in vivo by intravascular ultrasound. These findings indicate that chronic treatment with atorvastatin directly decreases mitogen-induced Can mobilization, which we suggest is related to the spatial localization of Can stores.",
keywords = "Cholesterol, Confocal microscopy, Electron microscopy, Endothelin, Intravascular ultrasound, Porcine, Triglyceride",
author = "Wamhoff, {B. R.} and Dixon, {J. L.} and Michael Sturek",
year = "2002",
doi = "10.1159/000063686",
language = "English (US)",
volume = "39",
pages = "208--220",
journal = "Journal of Vascular Research",
issn = "1018-1172",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Atorvastatin treatment prevents alterations in coronary smooth muscle nuclear Ca2+ signaling in diabetic dyslipidemia

AU - Wamhoff, B. R.

AU - Dixon, J. L.

AU - Sturek, Michael

PY - 2002

Y1 - 2002

N2 - Atorvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, alters bulk myoplasmic Ca2+regulation and inhibits phenotypic modulation and proliferation of vascular smooth muscle in culture. Nuclear Ca2+ (Can) signaling is tightly coupled to transcriptional events and cell growth. Therefore, we hypothesized that in vivo treatment with atorvastatin would attenuate alterations in mitogen-induced Can signaling associated with coronary atherosclerosis. Three groups of male Yucatan pigs were treated for 20 weeks: controls, alloxan-induced diabetics fed an atherogenic diet and diabetics fed an atherogenic diet plus atorvastatin (80 mg/day). Right coronary artery single-cell cytosolic Ca2+ (Cac) and Can responses to the mitogen endothelin-1 (5 × 10-8M) were measured by laser confocal microscopy using the calcium indicator Fluo-4. We observed a 39% increase in Cac and a 52% increase in Can responses to endothelin-1 in cells from diabetic dyslipidemic arteries compared to control. These alterations were prevented in animals treated with atorvastatin. We show that during proliferation, the nucleus of a smooth muscle cell becomes rounded and loses the characteristic multilobular shape, clefts and invaginations. Consistent with this, a redistribution of Ca2+ stores from a transnuclear morphology in controls to a more perinuclear morphology occurred in cells from diabetic dyslipidemic arteries and was prevented by atorvastatin. In addition, the peak Can responses to endothelin-1 were inversely correlated (r = 0.712) with the extent of the transnuclear distribution of Ca2+ stores and directly correlated (r = 0.874) with the extent of atherosclerosis, as assessed in vivo by intravascular ultrasound. These findings indicate that chronic treatment with atorvastatin directly decreases mitogen-induced Can mobilization, which we suggest is related to the spatial localization of Can stores.

AB - Atorvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, alters bulk myoplasmic Ca2+regulation and inhibits phenotypic modulation and proliferation of vascular smooth muscle in culture. Nuclear Ca2+ (Can) signaling is tightly coupled to transcriptional events and cell growth. Therefore, we hypothesized that in vivo treatment with atorvastatin would attenuate alterations in mitogen-induced Can signaling associated with coronary atherosclerosis. Three groups of male Yucatan pigs were treated for 20 weeks: controls, alloxan-induced diabetics fed an atherogenic diet and diabetics fed an atherogenic diet plus atorvastatin (80 mg/day). Right coronary artery single-cell cytosolic Ca2+ (Cac) and Can responses to the mitogen endothelin-1 (5 × 10-8M) were measured by laser confocal microscopy using the calcium indicator Fluo-4. We observed a 39% increase in Cac and a 52% increase in Can responses to endothelin-1 in cells from diabetic dyslipidemic arteries compared to control. These alterations were prevented in animals treated with atorvastatin. We show that during proliferation, the nucleus of a smooth muscle cell becomes rounded and loses the characteristic multilobular shape, clefts and invaginations. Consistent with this, a redistribution of Ca2+ stores from a transnuclear morphology in controls to a more perinuclear morphology occurred in cells from diabetic dyslipidemic arteries and was prevented by atorvastatin. In addition, the peak Can responses to endothelin-1 were inversely correlated (r = 0.712) with the extent of the transnuclear distribution of Ca2+ stores and directly correlated (r = 0.874) with the extent of atherosclerosis, as assessed in vivo by intravascular ultrasound. These findings indicate that chronic treatment with atorvastatin directly decreases mitogen-induced Can mobilization, which we suggest is related to the spatial localization of Can stores.

KW - Cholesterol

KW - Confocal microscopy

KW - Electron microscopy

KW - Endothelin

KW - Intravascular ultrasound

KW - Porcine

KW - Triglyceride

UR - http://www.scopus.com/inward/record.url?scp=0036311931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036311931&partnerID=8YFLogxK

U2 - 10.1159/000063686

DO - 10.1159/000063686

M3 - Article

VL - 39

SP - 208

EP - 220

JO - Journal of Vascular Research

JF - Journal of Vascular Research

SN - 1018-1172

IS - 3

ER -